Viridian Therapeutics, Inc. (VRDN)

19.22 -0.34 (-1.74%) USD  |  NASDAQ  |  Oct 16, 13:27
More

Viridian Therapeutics SG&A Expense (TTM) : 151.65M for June 30, 2026

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 151.65M
March 31, 2026 116.89M
December 31, 2025 95.31M
September 30, 2025 77.23M
June 30, 2025 67.31M
March 31, 2025 63.16M
December 31, 2024 61.08M
September 30, 2024 78.49M
June 30, 2024 85.00M
March 31, 2024 88.19M
December 31, 2023 95.00M
September 30, 2023 71.86M
June 30, 2023 59.81M
March 31, 2023 48.65M
December 31, 2022 35.18M
September 30, 2022 32.23M
June 30, 2022 29.59M
March 31, 2022 28.00M
December 31, 2021 25.80M
September 30, 2021 24.44M
June 30, 2021 20.52M
March 31, 2021 16.70M
December 31, 2020 13.26M
September 30, 2020 10.26M
June 30, 2020 10.86M
Date Value
March 31, 2020 11.01M
December 31, 2019 11.65M
September 30, 2019 11.81M
June 30, 2019 11.60M
March 31, 2019 11.42M
December 31, 2018 11.05M
September 30, 2018 10.90M
June 30, 2018 10.71M
March 31, 2018 10.62M
December 31, 2017 10.91M
September 30, 2017 10.88M
June 30, 2017 10.43M
March 31, 2017 10.25M
December 31, 2016 9.583M
September 30, 2016 9.77M
June 30, 2016 10.52M
March 31, 2016 10.47M
December 31, 2015 10.25M
September 30, 2015 9.504M
June 30, 2015 8.691M
March 31, 2015 9.739M
December 31, 2014 7.715M
September 30, 2014 6.269M
June 30, 2014 4.840M
December 31, 2013 2.536M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Vertex Pharmaceuticals, Inc. 2.008B
TG Therapeutics, Inc. 296.46M
Travere Therapeutics, Inc. 396.39M
ACADIA Pharmaceuticals, Inc. 620.29M
Alnylam Pharmaceuticals, Inc. 1.318B